VRDN 005
Alternative Names: VRDN-005Latest Information Update: 02 Jul 2024
At a glance
- Originator Viridian Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 02 Jul 2024 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route) prior to July 2024 (Viridian Therapeutics pipeline, July 2024)
- 17 Mar 2023 Preclinical trials in Autoimmune disorders in USA (unspecified route) before March 2023 (Viridian Therapeutics pipeline, March 2023)
- 04 Feb 2021 Viridian therapeutics plans to files an IND application with the US FDA in 2022 (Viridian Therapeutics pipeline, February 2021)